These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20659956)

  • 1. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
    Jones JL; Anderson JM; Phuah CL; Fox EJ; Selmaj K; Margolin D; Lake SL; Palmer J; Thompson SJ; Wilkins A; Webber DJ; Compston DA; Coles AJ
    Brain; 2010 Aug; 133(Pt 8):2232-47. PubMed ID: 20659956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
    ; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
    N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
    Brown JW; Coles AJ
    Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on alemtuzumab.
    Jones JL; Coles AJ
    Int MS J; 2009 Sep; 16(3):77-81. PubMed ID: 19878629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Skoromets A; Stolyarov I; Bass A; Sullivan H; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Neurology; 2012 Apr; 78(14):1069-78. PubMed ID: 22442431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
    Klotz L; Meuth SG; Wiendl H
    Clin Immunol; 2012 Jan; 142(1):25-30. PubMed ID: 21550857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
    Graves J; Galetta SL; Palmer J; Margolin DH; Rizzo M; Bilbruck J; Balcer LJ
    Mult Scler; 2013 Sep; 19(10):1302-9. PubMed ID: 23459567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
    Hartung HP; Aktas O; Boyko AN
    Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
    Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
    CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
    Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
    Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
    Tuohy O; Costelloe L; Hill-Cawthorne G; Bjornson I; Harding K; Robertson N; May K; Button T; Azzopardi L; Kousin-Ezewu O; Fahey MT; Jones J; Compston DA; Coles A
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):208-15. PubMed ID: 24849515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
    Jones JL; Phuah CL; Cox AL; Thompson SA; Ban M; Shawcross J; Walton A; Sawcer SJ; Compston A; Coles AJ
    J Clin Invest; 2009 Jul; 119(7):2052-61. PubMed ID: 19546505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.